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ABSTRACT
Quality assurance (QA) guidelines are essential to provide uniform execution of clinical hyperthermia
treatments and trials. This document outlines the clinical and technical consequences of the specific
properties of interstitial heat delivery and specifies recommendations for hyperthermia administration
with interstitial techniques. Interstitial hyperthermia aims at tumor temperatures in the 40–44 C range
as an adjunct to radiation or chemotherapy. The clinical part of this document imparts specific clinical
experience of interstitial heat delivery to various tumor sites as well as recommended interstitial hyper-
thermia workflow and procedures. The second part describes technical requirements for quality assur-
ance of current interstitial heating equipment including electromagnetic (radiative and capacitive) and
ultrasound heating techniques. Detailed instructions are provided on characterization and documenta-
tion of the performance of interstitial hyperthermia applicators to achieve reproducible hyperthermia
treatments of uniform high quality. Output power and consequent temperature rise are the key
parameters for characterization of applicator performance in these QA guidelines. These characteristics
determine the specific maximum tumor size and depth that can be heated adequately. The guidelines
were developed by the ESHO Technical Committee with participation of senior STM members and
members of the Atzelsberg Circle.
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Introduction
These quality assurance (QA) guidelines for the application of
interstitial hyperthermia, as presented here, were developed
upon request of the Atzelsberg Circle for Clinical
Hyperthermia, which is the Interdisciplinary Working Group of
Hyperthermia ‘Interdisziplin€are Arbeitsgruppe Hyperthermie’
(IAH) [1] of the German Cancer Society (‘Deutsche
Krebsgesellschaft’) to the European Society for Hyperthermic
Oncology (ESHO) [2]. ESHO delegated this task to the ESHO
technical committee (ESHO-TC), who formulated the guide-
lines with participation of experienced members of the
Society for Thermal Medicine (STM) [3].
Goal: these guidelines aim to establish a single uniform
level of quality assurance and control in hyperthermia treat-
ments delivered in all multi-institutional studies initiated by
the Atzelsberg Circle or under the auspices of the ESHO. The
goal of this effort is to establish QA guidelines for the
application of interstitial hyperthermia (IHT), similar to the QA
guidelines for the administration of deep and superficial
hyperthermia defined earlier [4–7] and as follow-up to the ear-
lier QA guidelines for interstitial hyperthermia provided by
Radiation Therapy Oncology Group [8], earlier reviews on
interstitial technology [9,10] and the hyperthermia guidelines
by ESHO [11]. The technical properties and clinical practice
described in these earlier documents serve as starting point
for these updated and expanded guidelines. New in the
guidelines is more attention to the consequences of the het-
erogeneous temperature distributions and high-temperature
gradients during clinical interstitial hyperthermia. Furthermore,
detailed descriptions are included of standardized QA and
working procedures before, during and after clinical applica-
tion, all based on modern computer technology. Results from
these earlier documents are discussed when necessary for
understanding the rationale of these new guidelines.
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The guidelines serve as the current standard to facilitate
that the application and registration of interstitial hyperther-
mia treatments within clinical trials follow current knowledge
and experience both from technological and clinical consid-
erations. Consequently, participation in clinical trials requires
both implementation of these QA guidelines and strict
adherence to the specific requirements of the clinical study
protocol in order to apply hyperthermia to the defined clin-
ical target. Storing treatment data should preferably follow a
joint standard format [12]. It is the responsibility of every
institute to characterize its hyperthermia equipment and to
make the data available to the ESHO-TC. As a follow-up to
the development of these QA guidelines and use of the
experimental and clinical information obtained via the imple-
mentation of the QA guidelines, the ESHO-TC may formulate
a list of device types with a description of the potential
tumor size and location that can be heated.
The QA-IHT guidelines in this paper are intended for inter-
stitial devices used to generate hyperthermic temperatures
within a tumor volume that are predominantly within the
40–44 C range for 30–60min typical duration, as an adjunct
to radiation therapy [13], chemotherapy [14], and potentially
immunotherapy [15]. Hyperthermia delivered in this fashion
is targeted toward direct cytotoxicity of nutrient deprived
and hypoxic cells, and indirect cell kill by radiosensitization
and chemosensitization [16]. Although not covered in this
document, similar devices can be used to deliver thermal
ablation therapy, where temperatures exceeding 50–55 C
and a lethal thermal dose (>240 CEM43 C) are targeted
throughout the tumor and surrounding margin for producing
irreversible tissue destruction. The choice between applying
ablation or hyperthermia treatment is guided by tumor site-
specific considerations and clinical practice.
In particular, these QA-IHT guidelines summarize the char-
acteristics of interstitial heating and cover both technical and
clinical aspects of applying IHT and procedures to character-
ize the heating capabilities of IHT devices. When the QA-IHT
guidelines states ‘must’, strict application is required whereas
when it states ‘should’, implementation is strongly
recommended.
Part I. General definitions
I-A definition of IHT
Interstitial hyperthermia is a heating method using arrays of
needle-shaped applicators implanted directly or applicators
inserted within catheters that are implanted into the target
volume. Commonly treated tumor sites include brain, breast,
head and neck, cervix, prostate and bladder. Interstitial appli-
cators have a typical active length of 4–10 cm and a diam-
eter of 1–2mm. Due to steep radial fall-off of energy and
blood perfusion, heating penetration is limited for most
modalities to 5–10mm radius of tumor tissue around each
applicator, often dictating that multiple applicators be used.
Interstitial heating techniques are based on the same
heating principles as intracavitary and intraluminal techni-
ques, but energy is delivered from interstitial needles or
catheters implanted percutaneously into the tumor rather
than placed within natural body cavities like cervix, bladder,
esophagus and urethra. Benign prostatic hyperplasia may be
treated with intraluminal transurethral microwave thermo-
therapy in the 45–60 C range [17]. Intracavitary and intralu-
minal applicators may have active lengths similar to
interstitial applicators but are generally not used in multiap-
plicator arrays and the diameter can be larger, up to 30mm,
depending on size of the cavity involved. These QA guide-
lines are intended for interstitial hyperthermia, although
parts may be applicable to intraluminal and intracavitary
hyperthermia which may be considered a special case of
interstitial heating using only one applicator.
Although many considerations for QA-IHT are directly
comparable to QA considerations for other hyperthermia
treatment approaches, there are two major differences which
hamper direct transfer of knowledge/experience from exter-
nal heating technologies. For external hyperthermia, the
heating and radiotherapy delivery devices are used inde-
pendent of each other. In contrast, the clinical use of IHT sys-
tems is usually closely interlaced with brachytherapy as both
treatments use the same catheters. Hence, power deposition
in IHT is confined to the tumor region avoiding the risk of
treatment limiting hot spots in surrounding normal tissues,
which should lead to better tumor coverage. The compara-
tively thin rim of heated tissue margin around the heated
tumor volume creates a risk of heterogeneous and lower
temperatures in the tumor periphery due to the cooling
effect of incoming normothermic blood. Due to the steep
thermal gradient associated with highly localized IHT heat-
ing, achieving acceptable tumor temperature uniformity is
possible only with careful placement and spacing of the IHT
applicators and with adequate temperature control to
achieve a sufficiently high temperature between the applica-
tors without overheating the tissue close to the applicator.
Maintaining appropriate insertion lengths and parallel spac-
ing between catheters, sufficient implant catheters in the
periphery, along with adequate catheters for thermometry,
are critical points of which the radiation oncologist and sur-
geon must be aware during catheter implantation.
I-B definition of a minimum thermal dose requirement
for an interstitial hyperthermia treatment
A fundamental premise of these QA guidelines is that the
proven effectiveness of hyperthermia in clinical studies relies
exclusively on its thermal effect on tumors, which is depend-
ent on temperature and time [16,18–21]. For this reason,
interstitial hyperthermia treatments must be conducted using
hyperthermia devices that are technically capable of provid-
ing controlled heating of the specific target volume to the
required thermal dose range (as defined in part II) while min-
imizing dose to surrounding critical normal tissues and adja-
cent normal organs (‘organ at risk’ – OAR). The target
volume and organs/areas at risk are to be defined by the
responsible oncologist using imaging studies and/or physical
examination.
Current literature shows clinical evidence that the benefit
of hyperthermia exists only when hyperthermia is applied in
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combination with chemotherapy and/or radiotherapy.
Different protocols specify different thermal dose goals
depending on combinations with other therapeutic agents
like radiation or chemotherapy and location in the body. The
clinical protocol also defines the time interval between the
chemotherapy/radiotherapy and hyperthermia treatment ses-
sion, aiming for optimal sensitization of chemo- and radio-
therapy. In current practice, chemotherapy is applied just
before or simultaneously with hyperthermia, while radiother-
apy is generally applied within 1–4 h of hyperthermia to
enhance therapeutic ratio, that is, obtain significant thermal
enhancement in tumor while avoiding enhancing normal tis-
sue side effects [22]. In rare cases when technically feasible,
external beam radiotherapy and interstitial hyperthermia can
be applied simultaneously [23] to achieve the potentially
highest thermal enhancement possible [22,24].
In particular, a good interstitial hyperthermia treatment is
defined as heating the target volume above the minimum
prescribed thermal dose while maintaining critical normal tis-
sues below the maximum prescribed normal tissue thermal
dose. At each hyperthermia session, the goal temperature of
40–44 C in the target volume should be aimed for over a
period of 30–60min. This means that temperatures exceed-
ing 44 C can occur very close to the applicators due to the
steep temperature gradient characteristic of interstitial heat-
ing. Interpretation of the measured temperatures during
interstitial hyperthermia requires special consideration of the
steep energy decay and precise location of temperature sen-
sors (see Section II-E).
Part II. Clinical considerations
II-A clinical requirements on heating devices
An interstitial hyperthermia system should be capable of
increasing the temperature in the majority of the target vol-
ume to the desired therapeutic level of 40–44 C, with pos-
sibly higher temperatures (44 C to 48 C) localized in small
volumes immediately adjacent to the applicators. These
higher temperatures adjacent to the applicators should be
within the tumor target volume. To achieve this, an individ-
ual applicator should be able to deposit at least 0.5W/g in its
subvolume of the implant volume, see Section III-B for details
[25]. In order to produce more uniform heating, it should be
possible to control the output power of individual applica-
tors independently between 0% and 100% of max-
imum output.
IHT catheters are generally selected for use with proper-
ties suitable for brachytherapy, which only partly coincide
with requirements for hyperthermia. A property very relevant
for hyperthermia is the proportion of applicator power that
is absorbed in the catheter wall. Excessive self-heating of
catheters leads to a significant change of the physical mech-
anism of energy transfer. For radiative EM approaches, the
catheter should be made from electromagnetically (EM) loss-
less or lowloss materials like polytetrafluoroethylene (PTFE),
polyethylene (PE) or silicone. Most applicator designs are
matched to specific catheter materials and diameters in
order to achieve the desired power deposition patterns.
Thermal conduction hot sources also require specific cathe-
ters to achieve the correct temperature in tissue.
To generate more uniform heating independent of appli-
cator geometry, noncoherent or asynchronous excitation of
multiple applicators is generally preferred. Special care must
be given to interapplicator spacing, maintaining greater than
5mm separation, in order to minimize cross-coupling and
interaction between adjacent applicators and to achieve a
contiguous therapeutic temperature distribution above 40 C
iso-temperature level across all target tissue between
implanted sources. Due to the small diameter of interstitial
implants and sharp radial fall-off of the energy deposition
around each device, the temperature distributions through-
out the target are more heterogeneous compared to superfi-
cial heating, with generally unknown peak temperatures
located at the surface of the sources and valleys or dips in
temperature between implants. Use of phase steering to cor-
rect for cold spots is technically possible after careful hyper-
thermia treatment planning but difficult to implement
reliably in clinical practice as often positioning is imprecise
and insufficient thermometry is available for feedback.
Hence, synchronous excitation of applicators is generally not
preferred. Implanting of additional catheters to improve ther-
mal dose distribution and allow for adequate thermometry
should be considered. The important factor for a quality
treatment is to maintain a minimum therapeutic temperature
throughout the target, and thus, careful preplanning and
monitoring of temperature in the valleys between sources is
critical to successful treatment. Furthermore, care should be
taken regarding placement of applicators too close to the
body surface or bony structures to avoid perturbation of
expected applicator SAR pattern, feedline heating, and nor-
mal tissue toxicity.
II-B overview of existing (minimal) invasive heating
technologies
An overview of interstitial, intraluminal and intracavitary
heating technology can be found in Appendix B and in
[9,26,27], which describe nine distinct technologies for heat-
ing tissue with miniature implantable heat sources. These
documents summarize design concepts and typical perform-
ance for numerous implementations of these nine technolo-
gies which have resulted from University prototypes and
commercial production. The most common devices are: (i)
coaxial cable mounted microwave (MW) antennas [28] which
have been manufactured in a variety of monopole, dipole
and helical coil configurations; (ii) laser-irradiated fiberoptic
diffuser crystals [29]; and (iii) radiofrequency (RF) electrodes
that couple either resistively [30,31] or capacitively [32–34] to
surrounding tissue. For hyperthermia applications where
temperatures are restricted to a narrow 40–44 C window,
interstitially implanted sources heat roughly 5–10mm radius
cylindrical or ellipsoidal volumes so must be implanted in
arrays with 10mm or less spacing. In the special case of
using microwave synchronous phase array mode, the spacing
can be 20mm. The advantage of such a configuration is that
catheters of the 10mm spacing brachy implant can be left
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nonoccupied to be used for temperature probes providing
relevant feedback for RF-power control per applicator. When
high-density implant arrays close to 10mm spacing are clin-
ically feasible, thermal conduction only hot sources may be
used to produce relatively uniform heating within the inter-
ior of an array away from the periphery. Thus, there has
been considerable investigation of hot source techniques like
needle- or catheter-based hot water perfusion (HWP) [27,35],
DC resistance wires (RW) [36], and ferromagnetic seeds (FMS)
[37,38] which are unique in that no externalized connections
are required to couple energy from an external mag-
netic field.
Some of the above approaches have no provision to
adjust heating along the length of the implanted source
which limits homogeneity of heating and localization of heat
to just the tumor volume. To provide real-time adjustment of
heating along the implant length, other approaches have
been investigated [39–41]. Of the currently available intersti-
tial systems, the most adjustable patterns are possible from
capacitive coupled bipolar RF electrodes [32,42] and linear
array tubular ultrasound (US) transducers in either direct
coupled [43] or catheter-cooled [44] configurations. In par-
ticular, the ultrasound array applicators can provide precise
control over the angular as well as axial distribution of the
SAR [45]. Of the various technologies for interstitial hyper-
thermia, only MW antennas are commercially available; all
other devices are products of academic research groups.
Somewhat larger diameter sources based on the same
technologies as mentioned above have been used success-
fully for heating tissue surrounding natural body cavities
(e.g., urethra, rectum, esophagus, bile duct). This intracavitary
heating technology has been reviewed previously [10,46,47].
II-C specific considerations for IHT-treated tumor sites
Experience with the clinical application of IHT shows the
need for attention to a number of physical and (thermo)
physiological aspects of treatment for specific tumor sites.
The distribution, alignment and spacing of implanted cathe-
ters are often determined by the requirements and con-
straints for brachytherapy, and the resulting implant tends to
be suboptimal for hyperthermia. Spatial control over the
temperature distribution is achieved by power control of
individual applicators. Axial steering along the length of indi-
vidual applicators is not possible for many of the IHT applica-
tors. Moreover, poor alignment and heterogeneous catheter
spacing can cause hot and cold spots within the implant,
which might be enhanced when using coherent or synchron-
ous power to drive different applicators. Proximity of ana-
tomical structures with very low-power absorption like bone
and air/gas surface can also cause hot spots; this should be
taken into account when implanting the target region. Very
localized hot spots are acceptable as long as they are within
the macroscopic tumor and do not lead to pain complaints.
High perfusion levels are a major issue in many tumor
sites, including head and neck, brain and prostate where
high perfusion levels can produce significant temperature
heterogeneity [37]. Movement and changes in catheter
alignment, applicator insertion, and thermometry positioning
are other aspects that should be monitored and controlled.
Heating brain tumors requires more caution to avoid tox-
icity in surrounding thermally sensitive normal brain tissue as
patients are generally incapable of sensing either pain or
excessive temperatures in the brain. Monitoring of brain tem-
peratures in fully awake patients is critical so the patient can
report unusual sensations or neurological perturbations,
which correspond to the brain region treated. In some cases,
patients may respond with seizures during heat treatment,
especially in cases where the tumor is pressing upon motor
control areas of the brain. Some brain tumors, for example,
glioblastoma, are associated with microscopic infiltration
extending out into the surrounding normal brain tissue,
necessitating implantation of a comparatively large margin
of normal brain around the macroscopic tumor [23].
For base of tongue tumors, the main critical structures are
bones close to the target volume where excessive tempera-
tures should be avoided. Additionally the temperature distri-
bution can be heterogeneous due to heterogeneous
perfusion in this region and nonparallel catheter placement.
When curved catheters (e.g., loops) are used with an extreme
curvature, proper positioning of the hyperthermia applicators
can be compromised. Further, care must be taken to ensure
that catheter insertion and applicator insertion length are
sufficient to produce the desired power deposition pattern
while avoiding skin or entry site burns.
In the case of breast tumors, excessive temperature
should be avoided in critical tissues such as skin overlying
the breast, scar tissue, surgical skin flaps, and bony structures
if the target volume is close to the chest wall. For most
tumor sites, the tips of the brachytherapy catheters are
placed at the distal edge of the tumor, facilitating correct
positioning of the hyperthermia applicators as the active
heating region of most applicators also starts at the tip.
Correct positioning of applicators relative to the tumor target
requires more attention in the case of breast tumors
implanted with catheters exiting the skin on both ends and
having variable amount of normal tissue overlying the tumor
target. Potential movement of the applicators during treat-
ment is also an issue requiring precaution. Occasionally,
highly curved (e.g., looping) catheters are implanted for
brachytherapy in breast and head and neck cancers, which
may cause passage, positioning problems, and possibly
undesirable SAR patterns for hyperthermia as discussed ear-
lier for base of tongue tumors.
The critical structures for prostate tumors are the urethra,
neurovascular-bundles, bladder neck and wall, penile bulb,
and bowel and rectum. Causing damage to these structures
during catheter placement or treatment delivery should be
avoided. These structures are close to, or in the case of the
urethra, inside the target volume so a minimum therapeutic
temperature of 40 C is necessary although excessive temper-
atures >45 C should be avoided.
Generally, the catheters are placed and fixed using a tem-
plate during the entire treatment. This template is often
fixed to the target region using metallic needles. These
metallic fixation needles are recommended to be removed
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during hyperthermia to avoid unwanted excessive heating at
these metallic structures. Alternatively metallic fixation nee-
dles can be replaced with plastic anchoring catheters [48].
II-D recommended IHT treatment delivery
Figure 1 shows the workflow of IHT, which consists of: pre-
planning, catheter implantation, reconstruction, hyperthermia
treatment planning, treatment with heat up phase (I), thera-
peutic phase (II) and cool down phase (III), and finally docu-
mentation. The target volume is always defined by the
responsible clinician. Definition of the tumor volume, adja-
cent normal organs, OARs, and large vessels is one of the
most important aspects of the treatment planning process,
so it should incorporate the information from clinical examin-
ation and radiologic studies (US, computed tomography (CT),
magnetic resonance imaging (MRI), Positron-emission tomog-
raphy-computed tomography (PET-CT). CT or US guidance is
used to place the catheters into the tumor target volume. In
case of combining brachytherapy with hyperthermia, the
clinical target volumes for both treatments should be the
same. The geometry of the implant catheters should take
into account brachytherapy physics, as well as technical
properties of the heat sources [9] and the required number
and position of thermometry probes.
Preplanning
Pretreatment planning involves definition of the target vol-
ume by the responsible clinician, more specifically the num-
ber, location and orientation of IHT applicators and
thermometry to cover the desired target volume, taking into
account the required applicator alignment, spacing and mar-
gins needed to ensure adequate tumor heating. Both
patient-specific and generic nonpatient-specific planning
using published implantation guidelines for specific techni-
ques are acceptable [8,9]. Interstitial hyperthermia is gener-
ally applied using catheters implanted for brachytherapy, so
planning should take the implant requirements for both
radiotherapy and hyperthermia into account. A catheter
spacing of 10mm is optimal general practice for
both modalities.
Catheter implantation
a. Catheters for applicators should use materials compat-
ible with the hyperthermia technique used, for instance
plastic catheters without self-heating should be used in
conjunction with EM techniques [49]. Catheters should
be distributed homogeneously and parallel orientation
throughout the target volume including the periphery
to avoid hot spots as well as areas of underdosage. The
goal temperature is 40–44 C throughout the target vol-
ume combined with sparing of organs at risk and critical
structures. Homogeneity of heating will be improved by
reducing the spacing between catheters. Alternatively,
accepting higher temperatures close to the catheters
will help to reach the minimum temperature.
b. Catheters for thermometry should use the same materi-
als as catheters for applicators. They should be
placed at:
– representative locations for best sampling of target
temperature.
– expected cold regions, that is, at the periphery and at
target locations at a large distance from applicators
– close to critical structures
– expected hot spots
When single point thermometry probes are used, mapping
of the probes in the catheter should be applied, when pos-
sible. However, continuous multipoint thermometry is pre-
ferred over thermal mapping. The recommended number of
thermometry locations is given in Table 1, although a larger
number of thermometry locations matching or exceeding
number of independent applicators is preferred. A good
example of a thermometry scheme is given by Kukielka
et al. [50].
Figure 1. Schematic workflow of interstitial hyperthermia which consists of preplanning, catheter implantation, reconstruction, hyperthermia treatment planning,
treatment with heat up phase (I), therapeutic phase (II) and cool down phase (III), and finally documentation.
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Reconstruction
Reconstruction of the treatment setup should be performed
by 3D-imaging with CT, MR, or US with the patient in treat-
ment position including the IHT catheters or applicators.
Implant catheters should be visualized for proper tracking
and localization, using dummy inserts if needed to recognize
the catheter positions. The gross tumor volume (GTV) and
hyperthermia target volume (HTV) should be defined.
Planning
Definitive treatment planning: The actual/updated gross
tumor volume (GTV) and hyperthermia target volume (HTV)
should be defined in the 3D patient data set. Hereafter, the
physicist/engineer can calculate the tissue insertion length of
each catheter, the HTV along that length, the definite loca-
tion of the applicators and temperature probes together
with the steering parameters. If necessary, an offset to the
applicator or thermometry insertion can be applied to match
insertion depth to target volume.
Treatment
The operator should have all relevant data to control the
treatment (temperature, dose, power, time - history) pre-
sented in the graphical user interface (GUI). Safeguards to
detect and prevent malfunctioning of equipment, such as
reflected power monitoring, should be present. Applicators
and temperature probes are placed in the catheters.
Hereafter, the treatment starts using low power. During the
first 10min the power is stepwise increased, after every
power increase the temperatures and vital signs of the
patient are monitored. The remaining treatment time after
reaching steady-state (temperature T> 40 C) should be
between 30 to 60min. Temperatures should be recorded at
least every minute. If temperature mapping is used a cycle
time for the temperature profiles of at most 5–10min is rec-
ommended. Recording the temperature decay for several
minutes after turning off the power is recommended. Most if
not all patients will be on epidural and pain meds already,
but during ‘breakthrough’ discomfort additional meds can be
given or the applied power distribution can be altered or
reduced if deemed necessary from patient feedback,.
Documentation
Treatment data to be recorded include temperatures of
tumor and normal tissues at risk, tumor thermal dose,
applied power to each applicator, temperature and flow of
the cooling medium (if applicable), and operator and patient
comments (e.g., pain). Calculating and recording temperature
parameters T50 and T90, the temperatures achieved in 50%
and 90% of measured (tumor-related) points, respectively,
and CEM43T90 (CEM for ‘cumulative equivalent minutes’) is
recommended, but challenging in view of the heterogeneous
temperature distribution during IHT. Temperatures recorded
using dedicated thermometry catheters will generally provide
the minimum target temperature. Accurate dose distribution
data are needed to obtain reliable T90 and CEM43T90 corre-
lated with clinical response. The full list of parameters to
document is given in Section IV-B.
Throughout planning and treatment delivery, HT should
be done in such a way as to minimize impact on standard
brachytherapy practice.
Part III. Technical considerations
III-A key characteristics of interstitial applicator devices
Interstitial applicators in use today consist of MW antennas,
capacitively coupled radiofrequency catheter-based electro-
des (RF-CC), resistively coupled radiofrequency local current
field electrodes (RF-LCF), and ultrasound transducers. In gen-
eral, these devices deposit energy within a limited volume of
tissue close to the heating device(s). The operating principles
of various systems for interstitial heating have been reviewed
previously [9,51–53] and are summarized in Appendix B
and C.
Heating uniformity within an interstitial implant array is
highly dependent on: (i) modality and technical properties of
the applicator used; (ii) implant spacing and alignment; and
(iii) applicator position within each needle or catheter
implant relative to the skin and other applicators. The com-
parison of critical implant characteristics given in Table 2 for
four different interstitial heating techniques provides some
guidance in selecting the appropriate technique for a specific
tumor indication.
As indicated in Table 2, RF-LCF techniques are most sensi-
tive to parallel alignment of sources and MW antennas are
more sensitive to alignment than US segmented linear array
applicators that can be adjusted in power along the length
to accommodate variable distance between implants. An
important factor determining the required spacing is the
characteristic heat penetration depth (PD) of the applicator.
The PD of RF techniques is conservatively defined by 1/r2
falloff. Theoretically, higher PD can be achieved in the central
part of the target volume with an array of multiple parallel
MW applicators, if used in (nonrecommended) coherent
mode. A special case exists for synchronous or coherent
phase modes using a 20 20mm implant utilizing the non-
occupied catheters for temperature measurement and feed-
back. To cover larger target volumes, ultrasound devices
with the highest PD shall be preferably used to minimize the
Table 1. Recommended minimum number of temperature probes.
No. of heat
sources
No. of tumor volume
representative probes
No. of peripheral
probes
No. of probes in
the center of source
interspace
4–6 1 1 0
7–10 1 1 1
10–16 2 1 2
17–30 3 2 2
>30 3 2 3
The proposed number of temperature probes is the result of careful consid-
eration of the optimum use of available catheters to insert sufficient applica-
tors to obtain a high quality temperature distribution vs. a hesitance to insert
additional catheters that provide only temperature data.
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number of heating elements needed. This increase in PD jus-
tifies an increase in required implant array spacing from 10-
15mm for RF-CC/RF-LCF/MW techniques to 15–20mm for US
transducers, as listed in Table 2. The PD of MW antennas can
be improved by selecting a lower operating frequency up to
a certain limit [54]. Some techniques apply internal cooling
to reduce the maximum temperature at the applicator sur-
face. This allows the operator to raise the applied power
without overheating the applicator surface, effectively
increasing the PD by a few mm. This allows a corresponding
increase in implant spacing over non-cooled applicators. A
practical implication for this approach is that maximum tem-
perature Tmax cannot be acquired in or near the applicator.
III-B characterization of heating properties
The implant/applicator is usually characterized as a single
device, but clinically applied in an array of applicators. An
IHT system should be capable of increasing the temperature
throughout the target volume to the desired therapeutic
range of 40–44 C. To achieve this, an individual implant/
applicator should be able to deposit at least 0.5W/g in its
subvolume of the implant volume [25,55]. Characterization of
the applicator’s heating properties should be performed
annually and consist of measuring the heating pattern
(Figure 2(b)) and its efficiency (Figure 2(c)).
(1) Single applicator
Prior to clinical use, the properties of the IHT system must
be characterized. First, it has to be demonstrated whether
the effective heating length (EHL) is sensitive for insertion
depth. The minimum dimension of the experimental setup
to characterize the IHT system are shown in Figure 2(a).
Therefore the temperature pattern must be measured for
two different insertion depths, for example, 5 and 25mm
between the phantom surface and the active part of the
applicator, in a split muscle equivalent phantom used in
combination either with an IR camera (preferred) or with
liquid crystal film [56] which both need calibration before
use, with a resolution of ±0.1 C and relative accuracy
0.05 C; spatial resolution 0.5–1mm [7] (Figure 2(b)).
These patterns should be available for the physicist prior to
geometric planning. EM field measurements using E-field
probes is not recommend, due to severe limitations with
spatial resolution [57,58]. Furthermore, a calorimetric meas-
urement to determine efficiency of the applicator must be
performed as described by Wilkinson et al [59] (Figure 2(c)).
Knowledge of applicator efficiency is mandatory for hyper-
thermia treatment planning or setting power output per
applicator using synchronous or coherent arrays.
In general MW, RF-CC and Ultrasound interstitial applica-
tors are used without counter electrodes. Only for RF-LCF the
application is mostly with a single ‘hot’ electrode and a large
counter electrode outside but against the body surface. For
all these cases, the characteristic heating properties can be
assessed as described in next sections. In rare cases, RF-LCF
heating is achieved by using two internal electrodes. For this
special case, the characteristic heating properties can also be
assessed using the description below, but the single applica-
tor has to be replaced by the dual electrode setup and the
diameter of the phantom cylinder has to be doubled. Hence,
the picture in Figure 2(b)) holds two electrodes with heat-
ing patterns.
Temperature rise criteria for adequate heating
An interstitial heating applicator is considered adequate/
appropriate if a temperature rise (TR) of 6 C above the start-
ing temperature can be achieved in 6min in a muscle-
equivalent phantom [7], around the applicator at 5mm, in
general a distance equal to half the implant spacing,
Figure 2(b).
The effective heating length depends on the applicator
design and can be determined using the measurement
described in section III-B (1). The EHL is characterized by a
thermal profile in the vertical plane, as shown in Figure 2(b).
Similarly to Emami et al [8], the EHL is defined as the length
at which the temperature rise (TR) is 50% or more of the
maximum TR (i.e., temperature difference DT 3 C) obtained
a constant distance of 5mm from the applicator. The phan-
tom can be cylindrical as shown in Figure 2, or flat but
should be sufficiently large to show the entire heat-
ing pattern.
Table 2. Comparison of device characteristics for four interstitial heating modalities.
Factor RF-CC RF-LCF MW Ultrasound
Longitudinal SAR uniformity þþ - - þ þ þ
Longitudinal SAR adjustability o - - /þa þ þ
Robustness of SAR to non-parallel alignments in array o - - o þ
Spacing between applicators [mm] 10–15 10–15 10–15; 20b 15–20
Thermometry at catheter feasible with applicator insertedc þ na – o
Catheter gauge 15 G 15 G 15 g 13–14 G
Compatible with brachytherapy catheters Yes Yes Yes No
Compatible with
- metal thermometry probes /þd – /þe þ
- nonmetal thermometry probes þþ þþ þþ –
The performance is indicated by following grades: þþ: very good; þ: good; o: fair; -: poor; –: very poor.
a’-‘ applies for MW dipole antennas; ‘þ’ applies for MW helical coil antennas.
bfor coherent use the spacing can be 20mm.
calthough feasible it is rarely used and mostly indicates only maximum temperature; not applicable (na) for RF-LCF as it uses long metal needles with high ther-
mal conductivity.
dwhen placed in dedicated thermometry catheter.
efor temperature probes placement perpendicular to E-field direction:  no RF-filtering; ‘þ’ with RF-filtering.
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Note that besides characterizing the temperature distribu-
tion, the effectively applied power must be measured annu-
ally. This can be accomplished with a calorimetric method
using a cylinder of which the diameter depends on the heat-
ing device (Figure 2(c)). The diameter of the cylinder should
be much larger than the implant spacing to reduce the
effects of the outer boundary on the measurement; and
>30mm minimum irrespective of applicator type.
Theoretically, it seems possible to calculate the total
absorbed power from average temperature rise (aTR) meas-
urements, but this approach has limited accuracy since it
includes self-heating of the applicator as well as the EM
deposited energy.
Thus Figure 2(c) shows the appropriate setup for calori-
metric/effective power measurements. The applicator within
the planned brachytherapy catheter is immersed in a
Styrofoam isolated cylinder of given diameter with a length
of a liquid muscle-equivalent phantom [60] matching the
active length of the applicator, where the phantom should
extend 15mm before and after the active part of applicator.
The initial temperature of the phantom must be known, typ-
ically at room temperature or other stable uniform tempera-
ture. The maximum power is applied for maximally 6min to
achieve at least a 6 C temperature rise. As an example: to
increase the temperature of a saline volume by 6 C during a
6min heating time an average SAR of 70W/kg is required.
For a 3 cm diameter cylinder that is 10 cm long (i.e., a vol-
ume of 70.9 cm3 and a weight of 0.0709 kg), this translates in
an applied power level of 5W. The aTR in the phantom is
measured before and after by a temperature probe following
good mixing of the liquid to obtain a homogeneous
temperature. The effective power emitted by the applicator
can be calculated from the relation
Pa ¼ q  cw  V  dT=dt; J=s ¼ W½ ;
in which Pa is absorbed power, q is the density and cw is the
specific heat capacity of the muscle-equivalent saline water,
V is the volume, dT the temperature increase, dt is the dur-
ation of heating. Alternatively, if other liquid media are used
the calorimeter can be calibrated by a resistance wire heat-
ing element, and direct current (DC) and applied voltage
measured to provide dT per unit power deposited.
(2) Array of applicators
It is important to verify to which degree applicators are per-
forming independently regarding heating pattern and power
output of each applicator, and whether these remain stable
and controllable when other applicators power channels in
the array are switched on or off. Such a test should be done
with an asynchronous or incoherent phase mode for these
channels. Generally, each applicator is operated by a separ-
ate, independently controlled power control channel.
Verification of this independence is particularly important
when multiple applicators are connected to a single power
channel, for example, through a power splitter or similar
device. The setup shown in Figure 3 should be used to test
and verify the stability of the heating pattern of applicators
within an array as individual applicator or part of an applica-
tor array operated by a single power control. LCF applicators
are more sensitive for misbalance when multiple applicators
Figure 2. The two main experimental setups to characterize the heating properties of an interstitial applicator. (a) Schematic setup to determine the effective heat-
ing length and the average temperature rise (aTR) in muscle equivalent phantoms, (b) Determination of the effective heating length in a solid phantom and using
infrared imaging (DTmax 6 C), (c) Calorimetric setup to determine the applicator efficacy in a liquid phantom for 6min heating time. The temperature–time pro-
file must be measured 5min before and after the heating and continuing during heating while continuously homogenizing the liquid to obtain the correct average
temperature. The minimum average DT must be 6 C.
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are operated by a single power control than MW applicators
using a calibrated power divider.
	 The first test involves the temperature distribution in the
horizontal plane through the maxima of Tmax when all
applicators are switched on as depicted in Figure 3(b).
This requires a phantom filled with a muscle equivalent
gel which can be split at the mid horizontal plane to per-
mit recording of the temperature distribution using a
thermographic camera as outlined in the superficial
hyperthermia guidelines [6,7].
	 The test of the stability of the heating pattern of applica-
tors and their generators is performed using an implant
of three applicators inserted in a phantom filled with a
muscle equivalent gel as depicted in Figure 3(a). A tem-
perature probe is inserted at 5mm distance from each
applicator to monitor the effective output of each appli-
cator. Applicators should be switched on and off in differ-
ent configurations with the objective to establish that the
effective power output of each applicator remains stable
independent of the on/off status of the other two appli-
cators. In this case, the RF-LCF applicators must be oper-
ated as a unipolar system with a large ground plate
connected to tissue. In systems using multiple applicators
per power channel, the applicators should be connected
to a single channel as well as distributed over different
channels. An example is given for three applicators. We
will compare the effective output power by continuously
measuring the temperature rise close to the first applica-
tor during 3minutes of power on for three settings: 100,
101 and 111. For systems with a minimum measured
temperature, for example, 29 C for the BSD 500, the
phantom will need to be prewarmed so that the stated
rise rate can be observed. The first experiment is the con-
trol measurement with one applicator switched on
(setting 100). In the second experiment, the first and third
applicators are switched on (setting 101). Any change in
effective output power as a result of switching on these
applicators indicates an influence of the generator as the
mutual distance of the first and third applicator is 40mm,
too large for direct interference between the applicators.
Finally, in the third experiment, all three applicators are
switched on (setting 111). This final measurement may
also establish a more direct interference between applica-
tors if switching on of this applicator at a closer distance
has more impact than switching on the furthest applica-
tor. The test should be performed as a single experiment,
that is, without moving applicators and temperature sen-
sors. A variation less than þ/-20% for each temperature
sensor/applicator pair within all three experiments is con-
sidered acceptable. The forward, reflected, and net power
should also be recorded for each applicator and test situ-
ation, and used for consistency. This procedure should
also establish that the output is indeed zero when an
applicator is switched off.
For testing an array of three applicators that share the
same RF power channel with a power divider or when an
array of three applicators are operated in a phase synchron-
ous mode, the simultaneous operation of all three applica-
tors with equal RF power should be tested to verify that the
measured heating rates do not vary by more than ±20%. If it
is not possible to switch connections to different applicators
of a power divider using a single channel than the applicator
cables should be connected or disconnected from the output
of the power splitter. For such a case, the input power to
the power divider would need to be changed so that the RF
power to each of these applicators would be the same. A
synchronous phased array of three applicators can have RF
power of individual channels switched on or off, but for such
Figure 3. Setup to verify independent performance of three applicators in an array. Experiments are required for three configurations with a different combination
of active applicators. (a) Setup to test the independence of the applicators and their generators, consisting of three applicators, each 20mm apart, and three tem-
perature probes indicated in black, each recording the temperature at 5mm of the active section of one applicator. (b) Example showing temperature distributions
in the horizontal plane at the position of the maxima of Tmax when one, two or three applicators are switched on. Green dots indicate power on, red dots
power off.
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a test the temperature sensor of the central applicator may
have a higher heating rate compared to the perimeter appli-
cators due to the synchronous phase additive effects when
all 3 applicators are operated.
III-C benefits of 3D treatment planning
Although 3D hyperthermia treatment planning systems are
scarcely used as a routine part of the interstitial hyperther-
mia workflow, they have great potential to increase the
insight and understanding of the quality of the applied heat
distribution. Phantom measurements are generally unable to
produce quantitative metrics like T10, T50, and T90, whereas
these parameters are readily calculated with treatment plan-
ning systems. The benefits of planning software are espe-
cially useful in cases of irregular implants which deviate from
equally spaced implants, or when insertion depths are vari-
able. Simulations can help to determine the required applica-
tor spacing for optimal target heating. If the insertion depth
is shallow for a particular source, care must be taken to
ensure that the SAR profile is as expected and not uninten-
tionally preferentially heating tissue proximal to the target
(e.g., bulb of penis, vaginal wall), or skin surface around the
entrance site. Hyperthermia treatment planning is generally
invaluable for initial evaluation of novel interstitial hyperther-
mia applicators or implant configurations.
For microwave heating using commercial systems, built-in
planning tools can be used to simulate heating according to
a user defined placement of the applicators and adjusted
phase and power settings. In general, an important aspect
for treatment planning in interstitial hyperthermia is accurate
modeling of the applicators. For capacitively coupled intersti-
tial electrodes, a grid-independent representation allows an
accurate description of irregular implants in heterogeneous
tissue [61]. Available techniques for modeling interstitial
ultrasound devices have been reviewed by Prakash et al.
[62]. In multi-element systems, the interaction between the
individual elements has a substantial impact on the achieved
temperature distribution. For instance, a graded-mesh finite-
difference time-domain (FDTD) code, together with an alter-
nate-direction-implicit finite-difference (ADI-FD) solution of
the bioheat equation, were used for studying arrays of
sleeved-slot antennas imbedded in a brain-equivalent phan-
tom [63]. Patient-specific temperature-based optimization
techniques are being developed for these complex systems
[64] and can be expected to improve future treatments.
At this time, the use of more detailed forward and opti-
mization-based treatment planning systems for interstitial
hyperthermia–is limited to a few academic centers that study
specific patient cases with, whenever possible, validation of
the predicted SAR/temperature distribution with measure-
ments made during the patient treatment [65,66]. From
these experiences, recommendations for treatment have
been formulated in the literature for some general cases
(e.g., implant technique, proximity of bone, insertion depths,
synchronous versus asynchronous operation) that can be
applied by the hyperthermia community [66,67].
Generic pretreatment planning is the minimum require-
ment and most basic form of planning system. This involves
computing the SAR and temperature distribution in an
equally spaced implant of applicators placed in an (semi)
infinite (half) space, assuming appropriate homogeneous tis-
sue properties and perfusion. The characteristics of the heat-
ing device for various insertion depths into soft tissue need
to be accounted for. The reliability of generic planning is lim-
ited, but tumor temperatures will not be overestimated if
worst case assumptions are made regarding tissue and perfu-
sion properties, for example, assuming the maximally
increased tissue perfusion rate valid in response to hyper-
thermic temperatures. This generic pretreatment planning is
very useful to derive generic rules for implant properties
including active applicator length, spacing and location. If
available, individual patient-specific treatment planning is
recommended using relevant anatomical data with perfusion
and tissue properties acquired using CT, MRI or
US [64,67,68].
In clinical application, computer simulations are useful to
complement actual measurements and thereby estimate the
indexed temperatures T10, T50 and T90, particularly in view
of the high gradients, small heated volume, and potentially
complex interactions within multi-element systems.
Nevertheless it is important to take into account the
uncertainties and limitations of the temperature simulation
in the planning systems.
IV. Protocol compliance, staff and documentation
IV-A demands on personnel
Hyperthermia is a multidisciplinary treatment involving com-
plex interrelated clinical and technical aspects. It requires
input and close cooperation of radiation oncologists, medical
oncologists, medical physicists, engineers, technicians, nurses
and in some cases surgeons and anesthesiologists.
Recommendations and responsibilities for all hyperthermia
treatment staff, with the exception of surgeons, are summar-
ized in [4,69]. Local and country-specific regulations must
be respected.
(a) Hyperthermia training
For the staff members who actually apply the interstitial
hyperthermia practical training in the form of active partici-
pation at an established hyperthermia center is required, in
addition to their main qualification. Adequate practical train-
ing is defined as at least 10 treatment sessions be performed
with the heating system in 3–5 different patients, under the
guidance of an experienced user. If the person in training
has experiences with other hyperthermia modalities (at least
1 year superficial/deep HT), the required training reduces to
five treatment sessions. It is recommended that the training
period is completed in 6months. Staff members who just
take care of the patients’ well-being and are not directly
involved in the application of the interstitial hyperthermia
need only a basic training on the principles hyperthermia
and the possible physiological effects of interstitial heating.
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A modified training procedure can be discussed with ESHO
in case of severe practical obstacles, for example, the
absence of an established interstitial hyperthermia institute
within a reasonable distance.
(b) Physicians
Interstitial Hyperthermia treatments are performed under the
supervision of a radiation oncologist who has been
adequately trained in either brachytherapy and/or theory
and clinical practice of interstitial hyperthermia. The phys-
ician is responsible for all clinical aspects of the hyperthermia
treatment (e.g., diagnosis, imaging, patient selection,
treatment prescription, fractionation, documentation).
The physician is responsible for implantation of an appropri-
ate high-quality hyperthermia catheters implant. This
includes complete coverage of the target volume, protection
of organs at risk, and optimal separation and parallel orienta-
tion of catheters. The physician should understand the limita-
tions of interstitial heating technology when placing the
implant catheters, to ensure optimal insertion length, align-
ment, and density for both radiation and hyperthermia con-
siderations. In case of a challenging location, the physician
can invite a surgeon to place the implant catheters. Further,
the physician also takes care of additional medications for
pain management and breakthrough pain if needed.
(c) Physicists/engineers
An adequately trained physicist or engineer is responsible for
the physical and technical aspects of the hyperthermia sys-
tem (e.g., quality assurance and consistency checks, specify-
ing the technical treatment parameters, intervention in case
of technical failures, phantom measurements, physical–tech-
nical part of the treatment planning) as described in this
document. In the preplanning phase, the physicist/engineer
must always advise the initial setup with the oncologist,
which defines the desired catheter positions and optimized
power delivery preplan.
(d) Technicians
The interstitial hyperthermia treatment can be assigned to a
hyperthermia trained assistant, for example a Radiation
Therapist or Radiographer under the direct supervision of a
physician and physicist. The technical assistant should be
specifically trained in the application of interstitial hyperther-
mia, with minimum training defined in section a) above. If
the hyperthermia equipment is operated by a technician, the
responsible physicist must be on-call and ready to take direct
action (maximum acceptable response time 5min).
(e) Nurses
Nurses can support a medical technician to perform intersti-
tial hyperthermia treatments after completing a training pro-
gram. In most institutes, nurses are involved in the
preparation of patients for the hyperthermia treatment and
are responsible for the well-being of the patient (e.g., assist
with placement of interstitial catheters for applicators and
thermometry, monitoring of patient vital signs during ther-
apy, administration of analgesics and pain medications, etc.).
When properly trained according to the physicist or treat-
ment technician requirements above, the nurse may perform
the hyperthermia treatment.
(f) Anesthetists
When sedation of the patient is required, an anesthetist per-
forms all relevant actions. A potential assistant must be for-
mally trained in anesthesia.
(g) Arranging substitutes
As in many other clinical treatments, two of the previously
described responsible professionals must be present at the
beginning of each treatment session in order to take care of
the patient, to control the hyperthermia device, and to guar-
antee correct implementation and verification of all aspects
of the standard operational procedure (SOP). During treat-
ment, one person might be sufficient if the other is available
on call. When interstitial hyperthermia is applied in combin-
ation with chemotherapy, a second person is responsible for
the chemotherapy application as described in the SOP for
chemotherapy.
IV-B treatment documentation
Treatment documentation varies for different complexity lev-
els of clinical use of IHT. The minimum data set required to
reconstruct the treatment quality of ‘a standard treatment’ is
defined below. Multicenter trials and dose effect studies gen-
erally require a higher level of documentation as summarized
in Appendix A.
Interstitial hyperthermia presents an opportunity for tem-
perature measurement directly within and adjacent to
tumors at depth which is generally not possible with superfi-
cial temperature monitoring. Rigorous temperature measure-
ment throughout the treatment region is encouraged,
balanced with practical treatment considerations including
the total number of catheters required for radiation treat-
ment and temperature probe placement.
Temperature data are preferably reported using maximal,
minimal and average temperatures Tmax, Tmin, Tave, and the
temperature parameters T10, T50, and T90, which are the tem-
peratures achieved in 10%, 50% and 90% of (tumor-related)
measured points, respectively. These parameters give a fair rep-
resentation of the temperature distribution during treatment
when a sufficient number of temperatures are monitored with
appropriate spatial sampling as described in the clinical study
protocol. Thus the number of sensors and the volume enclosed
by the sensors in relation to the target volume should be
recorded to reflect the quality of the temperature dosimetry.
When analyzing the achieved temperatures during IHT,
attention must be given to the position of the thermal sensors
with respect to the applicators. Temperatures recorded using
sensors placed separately in tissue between sensors typically
correlate with cold spots, giving values close to Tmin and T90.
Sensors integrated within or adjacent to the applicators
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generally provide information about maximal temperatures
Tmax and T10. Moreover, there are variations of temperature
along the length of the applicators so that higher quality dos-
imetry results from increasing the number of measurement
locations along each temperature monitoring catheter as well
as the number of probes/catheters. Placement of temperature
points and mapping to include tumor periphery at the distal
and proximal extent of implant, and within the implant inter-
ior are all critical to assess the quality of delivered treatment.
However, the perimeter of tumors is generally well-perfused
making those tissues more sensitive to radiation or chemo-
therapy alone. So the clinical impact of adding IHT may have
more importance based on the temperatures within the more
necrotic portions of the tumor that would be more resistant
to radiation or chemotherapy.
Minimum requirements for data reporting
All treatment relevant system control parameters (e.g.,
power, reflection, etc.) as well as all temperature measure-
ment values must be stored at regular time intervals, for
example, every five minutes. Changes to the treatment
parameters must be documented with chronological refer-
ence. Temperatures must be documented in a manner that
they can be related chronologically to the corresponding
measurement location. Further, logging must be performed
of power-related pain, pain caused by the position of the
applicator or the applicator itself, treatment interruptions or
early termination. Acute and late toxicities must also be
recorded. Storing treatment data should preferably follow a
joint standard format. The published data standard for the
storage and interchange of hyperthermia clinical data could
serve as a starting point to address this issue [12].
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Appendix A
Analysis and documentation of treatments mandatory
for institutes participating in clinical trials and
recommended in general
Temperature data are preferably reported maximal, minimal and average
temperatures Tmax, Tmin, Tave, and the temperature parameters T10, T50,
and T90, which are the temperatures achieved in 10%, 50% and 90% of
(tumor-related) measured points, respectively. These parameters give a
fair representation of the temperature distribution during treatment
when a sufficient number of temperatures are monitored with appropri-
ate spatial sampling as described in the clinical study protocol. Thus, the
number of sensors and the volume enclosed by the sensors in relation
to the target volume should be recorded to reflect the quality of the
thermal dosimetry (e.g., does it include peripheral as well as central
tumor monitoring). Thermal dose accumulates as a nonlinear function of
temperature and linear function of time and is preferably reported as
Cumulative Equivalent Minutes (CEM) T50 and T90 at 43 C, that is,
CEM43T50 and CEM43T90 respectively [4,5,21].
The exact evaluation procedure to be followed is prescribed by the
particular study protocols, but in general good documentation encom-
passes the following items:
	 Treatment efficacy:
	 Tumor response: complete response (CR), partial response (PR), sta-
ble disease (SD) and progressive disease (PD) following the inter-
national definitions for these evaluation criteria.
	 Tumor regression grade (TRG) according to Mandard or Dworak scale
for patients undergoing tumor resection after initial treatment with
hyperthermia.
	 Tumor downstaging by T and N parameters using the latest TNM
classification.
	 Survival analysis following the international practice and definitions
	 Toxicity using the latest version of the standard CTCAE scoring list:
	 Acute Toxicity (treatment-related toxicity occurring during treatment
and/or within 3 months after completing the treatment)
	 Late toxicity (treatment related toxicity persisting or occurring after 3
months after completing the treatment)
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Further, each clinical study protocol under the auspices of ESHO will
be executed in accordance to the latest ESHO quality assurance guide-
lines and will include the following statements:
a. An audit of the participating institute will be performed to validate
that documentation is in accordance with the study protocol.
b. A site visit will be performed by a member of the ESHO-TC.
Selection of this person will be in close cooperation with the princi-
pal investigator of the study, the institute’s local study coordinator,
the chair of the Medical Committee of ESHO, and the chair of the
ESHO-TC.
c. The institution that will be visited is responsible for the support
(traveling, lodging and time) of the auditor.
The following points should be considered for evaluating clinically
relevant hyperthermia studies:
1. Patient selection for trial participation
Before starting the therapy, a qualified physician must define the
indications for the hyperthermia treatment, regarding the inclusion
and exclusion criteria as defined in either local or multi-institu-
tional protocols.
2. Documentation
The documentation includes a clinical part, as well as a
physical–technical part. When the patient agrees to participate in
the clinical study, a hard copy of the informed consent signed by
the patient and MD must be stored. Duration of storage is pre-
scribed by national guidelines. The local situation of the designated
treatment field should be documented with pictures.
For patient-related medical data, protection regulations and doc-
tor–patient confidentiality apply. Availability and readability of the
treatment-relevant data must be ensured for the period specified
by the clinical protocol and (inter)national law.
2.1. Physical–technical documentation
All treatment relevant system control parameters (e.g., power, reflec-
tion, etc.) as well as all temperature measurement values must be
stored electronically in a retrievable fashion. Changes to the treat-
ment parameters must be documented with chronological reference.
Temperatures must be documented in a manner that they can be
related chronologically to the corresponding measurement location
and power delivery parameters.
(a) Data log of the course of treatment
Logging must be performed of: all temperatures, power, complaints
caused by position or power of the applicator, and treatment inter-
ruptions or early termination.
(b) Data log of the hyperthermia system
All hyperthermia device-related quality assurance data must be docu-
mented in the device logbook. The recordings must be according to
the existing national law (e.g., the German Medizinprodukte Gesetz
(MPG). Storing treatment data should preferably follow a joint stand-
ard format.
2.2. Clinical documentation
a. Informed consent with a list of potential side effects of adjuvant
hyperthermia is mandatory (according to national law).
b. Clinical Setup - Clinical documentation should describe the posi-
tions of patient, applicator, and temperature probes to allow repro-
duction of the treatment setup. For additional interstitial sensors,
additional CT, MRI and/or US imaging is recommended.
c. Medications (including cytotoxic drugs), concurrent radiotherapy,
and any other concurrent medical treatment.
d. Treatment related toxicity must be documented with a chrono-
logical reference to the hyperthermia treatment. Side effects that
are specifically caused by hyperthermia are primarily unwanted
high temperatures in the skin or nontarget tissues, especially in
patients with compromised temperature sensitivity, for example in
polyneuropathy or near surgical scars. Moderate temperatures may
be accompanied by false sensations, feelings of urgency for blad-
der or bowel release, or skin irritation, pain, and/or local edema. In
case of sustained overheating of tissue, tissue damage and necrosisTa
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may result. The temperature threshold for such irreversible damage
is approximately 44–46 C and 120–240 CEM43C thermal dose
depending on the tissue type. Specific side effects are given in
Table A-1. Hyperthermia treatment (in terms of these guidelines) is
not a single therapy mode, but supplements systemic chemother-
apy or radiation therapy. Side effects of the combined treatment
therefore correspond primarily with intensification of the spectrum
of side effects of chemotherapy or radiation therapy alone.
Classifying the side effects should follow the latest version of the
internationally established and accepted scoring systems (Common
Terminology Criteria for Adverse Events (CTCAE) and Quality
Management in Hyperthermia (QMHT). Worst grade toxicity sus-
tained up to 90 days from treatment initiation is classified as acute
toxicity. Worst grade toxicity sustained more than 90 days from
treatment initiation is classified as late toxicity. Physician reported
toxicity should be supplemented by patient reported outcomes
including quality of life using validated measures.
2.3 Standardization of the analysis of physical/technical treatment data
In order to create comparable analysis for all study participants, the
relevant data are extracted and, as far as possible, analyzed using
standard software.
Appendix B: Overview of historical and current
devices for interstitial heating
Interstitial applicators in use today consist of microwave antennas (MW),
resistively coupled radiofrequency local current field electrodes (RF-LCF),
capacitively coupled radiofrequency catheter-based electrodes (RF-CC),
ultrasound transducers (US), and various hot source techniques (HS). In
general, these devices deposit energy within a limited volume of tissue
close to the heating device(s). The operating principles of various sys-
tems for interstitial heating have been reviewed previously ([9,10,51,70]).
Interstitial microwave antennas have been constructed with numer-
ous variations of the radiating structure in attempts to optimize per-
formance for different tissue sites [15,40]. The most commonly available
commercial applicator is the BSD-500 – Pyrexar modified dipole antenna
model MA-251 (1.20mm OD) operating at 915MHz [71]. The radiating
portion is fixed in length as determined by wavelength constraints of
915MHz radiation. The applicator can be inserted within Nylon or
Celcon 15–15.5 gauge (1.74–1.8mm OD) or six French brachytherapy
implant catheters typically placed during an High-Dose Rate (HDR)
brachytherapy implant procedure. For insertion depths greater than
6 cm, the effectively heated portion (>10–25% SAR contour) is approxi-
mately 5 cm along the distal length of implant, potentially extending
beyond the tip. For a typical implant, multiple applicators are inserted in
catheters around the periphery and 1.0–2.0 cm apart within the GTV.
Depending upon alignment and separation distance, the applicator can
be operated in synchronous or asynchronous mode at the discretion of
the physicist to maximize uniformity of SAR distribution and extent
tumor heating. However, care must be taken when the insertion depths
and insertion angles are unequal. In this situation and with tumor axial
dimensions greater than 3 cm, the more conservative asynchronous
approach is recommended. When operating in synchronous mode, the
phase of each applicator with respect to the others can be modified to
steer the overall SAR distribution within the target and obtain more
selective central array heating. Regardless of phase relationship, feedline
heating and radiation pattern as a function of insertion depth need to
be accommodated in the treatment plan, to best ensure targeted heat-
ing of the tumor volume and minimization of surrounding normal tissue
heating. MW compatible high resistance lead thermistor probes or fiber-
optic probes are preferred, but thermocouples have also been used if
properly filtered and a minimum distance and perpendicular orientation
from the sources maintained.
Interstitial radiofrequency electrodes generate heating by resistive
losses of conduction currents between electrodes and can be divided in
two classes, resistively coupled radiofrequency local current field (RF-
LCF) electrodes which are in direct galvanic contact with the tissue and
capacitively coupled radiofrequency catheter-based electrodes (RF-CC).
RF-LCF electrodes relying on RF currents between metal electrodes are
straightforward in use and can be combined with simultaneous brachy-
therapy. The disadvantage is that the output of individual electrodes is
strongly dependent on the local electrical tissue properties and the loca-
tion and alignment of adjacent electrodes [8]. Interstitial capacitively
coupled radiofrequency catheter-based electrodes were designed to
overcome this issue by using segmented bipolar electrodes operating
from within catheters. The impedance associated with the catheter wall
far exceeds the tissue impedance, so RF-CC electrodes are less sensitive
to heterogeneous tissue properties and parallel alignment, and multi-
electrode applicators were developed to achieve 3-D control over the
spatial power deposition [33,34,42]. Multi-junction thermocouple probes
are integrated into the electrodes and are used for treatment monitoring
and feedback [72]. Interstitial hot source techniques have not been used
extensively, but good temperatures have been reported by several
groups [36,41,73].
Interstitial ultrasound applicators are currently under investigation for
delivery of hyperthermia within an HDR implant [42]. The unique and
advantageous property of ultrasound devices is that the radiating trans-
ducer portion can be segmented into separate tubular radiating ele-
ments along the catheter length and even separate sectors around the
tube surface. Each sector or segment can be operated under individual
power control to tailor the SAR to fit the tumor target or in response to
dynamic tissue changes. The short wavelengths for 5–10MHz radiators
ensure generation of well-directed energy patterns that are not suscep-
tible to change from variations in insertion depth or alignment angle,
such as is common for RF and MW devices. Typical configurations are
four to five 10mm long tubular transducers separated by 1mm; radiat-
ing either 360 deg (circumferential) or 210 deg (directional) sonication
patterns. The directional devices can be steered or directed toward the
center of the target volume, while the dead-zone or inactive region with
zero energy output can be positioned to provide protection of sensitive
tissues such as rectum or bladder. Multiple transducer directional ultra-
sound devices have been used for treatment of prostate and cervical
cancers [74–76]. These interstitial ultrasound devices are larger than MW
antennas, and thus require slightly larger 13 or 14 g Celcon Flexi-Guide
brachytherapy (2.2–2.4mm outside diameter (OD)) implant catheters,
compared to the 15–16 g commonly used for HDR brachytherapy. A
larger separation distance of 15–20mm is tolerable between applicators
due to the 1/r radial propagation (versus 1/r2 for RF) which produces
enhanced penetration depth of ultrasound compared to microwave.
Larger devices (e.g., 4mm OD) designed to fit within a standard HDR
tandem plastic catheter for the treatment of uterus and cervix, provide
directional and longitudinal control of power deposition to the cervix
[74–76]. It must be noted that ultrasound devices are generally more
complex to operate in that power levels must be controlled individually
to multiple elements after careful preplanning of the position and angle
of each implant catheter, and water-flow is required within each cath-
eter. Multi-junction thermocouple probes within adjacent catheters can
be used for treatment monitoring and feedback. Instead of associating
individual transducer segments to an individual temperature sensor, the
starting shape of power deposition can be applied and adjusted in mag-
nitude during the treatment as a simplification.
Quality assurance for ultrasound requires determination of the opti-
mal driving frequency for the applicator and the efficiency of electrical
input to acoustic power output. This characterization is typically per-
formed using an acoustic force-balance system [77]. The beam pattern
(equivalent to power deposition pattern) is typically measured in water
using a calibrated hydrophone and provides a direct representation of
the energy output pattern [45,78]. Further, tissue mimicking phantoms
for ultrasound can be used, either as a split phantom in conjunction
with an IR camera or using embedded temperature sensors for deter-
mination of the power deposition pattern.
Appendix C: Current devices for intracavitary and
intraluminal hyperthermia
As implied by the word intracavitary, hyperthermia is applied only to
heat tissues surrounding natural body cavities (i.e., bladder, rectum,
vagina, cervix, and esophagus) or within an intraoperative cavity such as
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treatment of metastatic spread of cancer cells within the abdomen.
Extensive descriptions of the methodology and prospects of heating
nonmuscle invasive bladder cancer have been published recently in a
special issue of the Int. J. of Hyperthermia (Vol 32, Iss 4). As discussed in
the literature, several commercial systems are available for applying
hyperthermia in combination with chemotherapy for treating non-
muscle invasive bladder cancer [79–84]. In addition, commercial systems
are available for applying hyperthermic intraperitoneal chemotherapy for
the treatment of metastatic spread of cancer cells within the abdomen
[85–89]. For both intracavitary hyperthermia methods, the quality of
treatment strongly depends on fluid circulation, control of the chemo-
therapy application, and the surgical procedure. Hence, specific quality
assurance guidelines should be developed in due time for these treat-
ment modalities.
Endorectal ultrasound devices have been developed specifically for
prostate hyperthermia [70,90] and evaluated in clinical studies [91,92].
With this technique, a linear array of 1.5MHz tubular transducers with
individual power control provides longitudinal and angular control of
heating profiles 2–4 cm from the rectal wall – covering the entire pros-
tate and seminal vesicles without an increase in rectal toxicity [93]. An
expandable water-cooling jacket was used to provide good coupling
and protection of the rectal wall. Quality assurance for intraluminal ultra-
sound devices follows the same principles as those for intersti-
tial devices.
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